Open AccessInterleukin 8 and bronchial eosinophils in patients with asthma and cold airway hyperresponsiveness
Author(s) -
А. Б. Пирогов,
Anna Prikhodko,
Juliy M. Perelman
Publication year - 2022
Publication title -
bûlletenʹ fiziologii i patologii dyhaniâ
Language(s) - English
Resource type - Journals
ISSN - 1998-5029
DOI - 10.36604/1998-5029-2022-83-8-14
Subject(s) - medicine , asthma , bronchial hyperresponsiveness , hyperventilation , sputum , exhaled breath condensate , gastroenterology , inflammation , immunology , respiratory disease , lung , pathology , tuberculosis
Introduction. Cold airway hyperresponsiveness (CAHR) is common in patients with asthma. The effect of inhaled corticosteroid/long-acting β2-agonist therapy (ICS / LABA) on its severity, and the role of IL-8, and the eosino-philic profile of bronchial inflammation have not been studied. Aim. To study the dynamic relationship between the level of IL-8 and eosinophilic inflammation in the bronchi of asthma patients with CAHR using anti-inflammatory combined therapy with ICS / LABA. Materials and methods. Patients with asthma (n=59) received ICS / LABA for 24 weeks. The level of disease control (ACT, points), cellular composition of induced sputum (IS), bronchial response (ΔFEV1IHCA, %) to 3-minute isocapnic hyperventilation with cold (-20ºС) air (IHCA) was assessed. Exhaled breath condensate (EBC) was collected before and after the IHCA, in which the concentration of IL-8 (pg/mL) was determined. Results. Group 1 included 28 patients with CAHR (ΔFEV1IHCA = -14.1 ± 1.7%), group 2 included 31 patients with no response to cold bronchoprovocation (ΔFEV1IHCA = - 3.0 ± 2.4 %, p 0.05). The concentration of IL-8 before and after the IHCA test in group 1 was 131.2 ± 18.0 and 146.3 ± 23.5 pg/mL, respectively (p > 0.05), in group 2 it was 130.5 ± 8.8 and 149.9 ± 18.4 pg/mL, respectively (p>0.05). After treatment, the airway response to the IHCA significantly decreased in group 1 (ΔFEV1IHCA = - 8.8 ± 1.5 %, p 0.05). The level of asthma control in group 1 increased to 20.7 ± 1.6 ACT points (p 0.05), as did the number of eosinophils (8.0 ± 2.4 and 6.2 ± 3.1 %, p > 0.05). In group 2, the level of IL-8 before and after IHCA decreased from 89.2 ± 7.7 to 73.9 ± 10.3 pg/mL (p < 0.01), the concentration of eosinophils decreased from 4.7 ± 1.3 up to 1.5 ± 0.57 % (p < 0.05). Conclusion. 24-week therapy with ICS/LABA in patients with CAHR leads to improved asthma control, a decrease in the severity of cold bronchospasm, without being accompanied by changes in the level of IL-8, which affects the dynamics of the concentration of eosinophils in the bronchi.